October 7, 2016
Gibbs previously served as Senior Vice President, Head of General Medicines at Takeda Pharmaceuticals for the US Business Unit
Gibbs brings diverse background and proven track record to lead the launch of its next product, EDS-FLU (OPN-375), and all other commercial activities
Yardley, PA September 29, 2016 — OptiNose, Inc., a privately held specialty biopharmaceutical company, today announced the appointment of Tom Gibbs as Chief Commercial Officer. In this new role, Gibbs will be responsible for developing and executing the commercialization strategy of EDS-FLU (OPN-375), an investigational treatment in development for chronic nasal inflammatory diseases which has completed Phase 3 in subjects with nasal polyposis.